Citations

Showing 10 of 108104 citations.

Orbital Inflammation in an Adult With Crohn Disease
Vasudevan, Abhinav , Tooley, Andrea A. , Ida, Cristiane M.

Mayo Clinic

JAMA Ophthalmology | January 27, 2022 | Volume: 140 | Issue: 4 | Pages: 426

10.1001/jamaophthalmol.2021.4676 | PMID 35084454 Get It

Analysis of Registered Clinical Trials in Surgical Oncology, 2008-2020
Wong, Bonnie O. , Perera, Nirosha D. , Shen, Jolie , Turner, Brandon E. , Litt, Henry K. , Wren, Sherry M. , Turner, Brandon E , Wren, Sherry M , Mahipal, Amit

Mayo Clinic

JAMA Network Open | January 27, 2022 | Volume: 5 | Issue: 1 | Pages: e2145511

10.1001/jamanetworkopen.2021.45511 | PMID 35084485 Get It

Perfecting hysterosalpingography: Limitations to the use of disposable balloon catheter and its solution
Youssef, Youssef , Raju, Rubin , Sanya, Rahima, Abuzeid, Omar , Hebert, John, Abuzeid, Mostafa I. , Abuzeid, Mostafa

Mayo Clinic

International Journal of Gynecology & Obstetrics | January 27, 2022 | Volume: 158 | Issue: 3 | Pages: 736-741

10.1002/ijgo.14118 | PMID 35084737 Get It

AbstractObjectiveTo revive the use of the Kahn Uterine Trigger Cannula to overcome limitations associated with technical difficulties during hysterosalpingography (HSG) using the disposable balloon HSG catheter.MethodA case series was conducted of 17 patients who encountered technically difficult or incomplete HSG study while using a disposable HSG balloon catheter, also leading to false‐positive findings. Nine patients underwent a repeat HSG using a Kahn Uterine Trigger Cannula (Group 1). Eight patients underwent diagnostic laparoscopy and tubal perfusion testing using a Kahn Uterine Trigger Cannula (Group 2). The findings for each group in comparison to their initial HSG results using the disposable balloon HSG catheter are described.ResultsAll patients were noted to have patent fallopian tubes using a Kahn Uterine Trigger Cannula on repeat HSG or tubal perfusion testing during laparoscopy.ConclusionProviders who perform HSG studies should be familiar with the value of a Kahn Uterine Trigger Cannula when the traditional use of disposable HSG balloon catheter fails due to technical difficulty or incomplete study. The use of the Kahn Uterine Trigger Cannula in such situations can prevent inaccurate assessment and unnecessary interventions.
Description of telepharmacy services by emergency medicine pharmacists
Manuel, Francis C. , Wieruszewski, Erin D. , Brown, Caitlin S. , Russi, Christopher S. , Mattson, Alicia E

Mayo Clinic

American Journal of Health-System Pharmacy | January 27, 2022 | Volume: 79 | Issue: 11 | Pages: 873-880

10.1093/ajhp/zxac027 | PMID 35084439 Get It

Abstract Purpose Utilization of telemedicine and telepharmacy services has become increasingly popular, as specifically noted during the coronavirus disease 2019 (COVID-19) pandemic. This article describes the implementation of and services provided by emergency medicine pharmacists (EMPs) as part of a telemedicine team in the emergency department (ED). Summary This report describes the telemedicine and telepharmacy services provided to EDs in the Mayo Clinic Health System from the Mayo Clinic Rochester ED. Telepharmacy services provided by EMPs started in 2018. EMPs cover telepharmacy calls as part of their shift within the ED in Rochester. Recommendations and interventions are documented in the electronic medical record. A retrospective review evaluated interventions provided from November 18, 2018, through November 10, 2020. Baseline patient demographics, as well as the type and number of interventions provided by EMPs, hospital site, and time spent on the interventions, were collected. Telepharmacy consults could include multiple interventions and be classified as more than one type of intervention. During this time period, 24 pharmacists worked in the ED and were able to provide telepharmacy services. There were 279 consults included in this study, with 435 interventions. Most of the calls came from critical access hospitals (48.7%). The most common types of interventions documented were medication selection and dosing (n = 238), antimicrobials (n = 141), monitoring and follow-up (n = 65), discharge (n = 56), drug information (n = 55), and allergy review (n = 50). Conclusion Telepharmacy services can provide increased access to emergency medicine specialty pharmacists in areas that would not otherwise have these services.
A Tissue Engineered Construct for Laryngeal Regeneration: A Proof‐of‐Concept Device Design Study
Shah, Manisha , Myers, Cheryl , McPhail, Michael, Neubauer, Juergen, Struthers, Jason D. , Madsen, Cathy S., Grandjean, Danielle, Zacharias, Stephanie R. C. , Tchoukalova, Yourka D. , Lott, David G , Tchoukalova, Yourka , Myers, Cheryl E , Lott, David G.

Mayo Clinic

The Laryngoscope | January 27, 2022 | Volume: 132 | Issue: S9 | Pages: No page available

10.1002/lary.30029 | PMID 35084750 Get It

Objectives/HypothesisDevelop a patient‐specific tissue engineered construct for laryngeal reconstruction following a partial laryngectomy.Study DesignBench and animal research.MethodsA construct made from a porous polyethylene scaffold shaped in a canine‐specific configuration and seeded with autologous canine adipose‐derived stem cells in fibrin glue was implanted in a canine following a partial laryngectomy. After 1 year, the construct was first evaluated in vivo with high‐speed imaging and acoustic–aerodynamic measures. It was then explanted and evaluated histologically.ResultsThe canine study at 1 year revealed the construct provided voicing (barking) with acoustic and aerodynamic measures within normal ranges. The canine was able to eat and breathe normally without long‐term support. The construct was integrated with epithelialization of all areas except the medial portion of the vocal fold structure. No anti‐infective agents were needed after the standard perioperative medications were completed.ConclusionThis study provided a successful first step toward developing a patient‐specific composite construct for patients undergoing partial laryngectomies.Level of EvidenceNA Laryngoscope, 132:S1–S11, 2022
Intra-articular celecoxib improves knee extension regardless of surgical release in a rabbit model of arthrofibrosis
Trousdale, William H., Limberg, Afton K., Reina, Nicolas, Salib, Christopher G., Thaler, Roman, Dudakovic, Amel, Berry, Daniel J., Morrey, Mark E., Sanchez-Sotelo, Joaquin, Wijnen, Andre van, Abdel, Matthew P., Berry, Daniel J. , Wijnen, André J. van , van Wijnen, Andre J , Berry, Daniel J , Trousdale, William H., Limberg, Afton K., Reina, Nicolas, Salib, Christopher G., Thaler, Roman, Dudakovic, Amel, Berry, Daniel J., Morrey, Mark E., Sanchez-Sotelo, Joaquin, Abdel, Matthew P.

Mayo Clinic

Bone & Joint Research | January 27, 2022 | Volume: 11 | Issue: 1 | Pages: 32-39

10.1302/2046-3758.111.bjr-2021-0546.r1 | PMID 35084209 Get It

Aims Outcomes of current operative treatments for arthrofibrosis after total knee arthroplasty (TKA) are not consistently positive or predictable. Pharmacological in vivo studies have focused mostly on prevention of arthrofibrosis. This study used a rabbit model to evaluate intra-articular (IA) effects of celecoxib in treating contracted knees alone, or in combination with capsular release. Methods A total of 24 rabbits underwent contracture-forming surgery with knee immobilization followed by remobilization surgery at eight weeks. At remobilization, one cohort underwent capsular release (n = 12), while the other cohort did not (n = 12). Both groups were divided into two subcohorts (n = 6 each) – one receiving IA injections of celecoxib, and the other receiving injections of vehicle solution (injections every day for two weeks after remobilization). Passive extension angle (PEA) was assessed in live rabbits at 10, 16, and 24 weeks, and disarticulated limbs were analyzed for capsular stiffness at 24 weeks. Results IA celecoxib resulted in greater mean PEA at ten weeks (69.6° (SD 4.6) vs 45.2° (SD 9.6), p = 0.004), 16 weeks (109.8° (SD 24.2) vs 60.9° (SD10.9), p = 0.004), and 24 weeks (101.0° (SD 8.0) vs 66.3° (SD 5.8), p = 0.004). Capsular stiffness was significantly reduced with IA celecoxib (2.72 Newton per cm (N·cm)/° (SD 1.04), p = 0.008), capsular release (2.41 N·cm/° (SD 0.80), p = 0.008), and capsular release combined with IA celecoxib (3.56 N·cm/° (SD 0.99), p = 0.018) relative to IA vehicle (6.09 N·cm/° (SD 1.64)). Conclusion IA injections of a celecoxib led to significant improvements in passive extension angles, with reduced capsular stiffness, when administered to rabbit knees with established experimental contracture. Celecoxib was superior to surgical release, and the combination of celecoxib and a surgical release did not provide any additional value. Cite this article: Bone Joint Res 2022;11(1):32–39.
Unusual Ultrasound Findings in a Difficult to Cannulate Arteriovenous Graft
Gossett, Christy L. , Kattah, Andrea G., Qureshi, Fawad, Gossett, Christy L. , Kattah, Andrea G., Qureshi, Fawad

Mayo Clinic

Kidney360 | January 27, 2022 | Volume: 3 | Issue: 1 | Pages: 192-193

10.34067/kid.0003952021 | PMID 35368558 Get It

Lower Extremity Injury After Return to Sports From Concussion: A Systematic Review
Jildeh, Toufic R. , Castle, Joshua , Buckley, Patrick J. , Hegde, Yash, Okoroha, Kelechi R. , Buckley, Patrick J., Abbas, Muhammad J.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | January 27, 2022 | Volume: 10 | Issue: 1 | Pages: No page available

10.1177/23259671211068438 | PMID 35111864 Get It

Background: Recent studies have suggested increased rates of lower extremity (LE) musculoskeletal injury after a diagnosed concussion, although significant heterogeneity exists. Purpose: To examine the current body of research and determine whether there is an increased risk for LE musculoskeletal injury after a concussion and to identify populations at an increased risk. Study Design: Systematic review; Level of evidence, 3. Methods: A systematic review of current literature using MEDLINE and PubMed databases was performed. Keywords included concussion, athlete, lower extremity injury, and return to sport. Inclusion criteria required original research articles written in the English language examining the rate of LE injuries after a diagnosed concussion. Results: A total of 13 studies involving 4349 athletes (88.1% male and 11.9% female; mean age, 19.8 years) met inclusion criteria. Athletes were classified as high school (46.1%), collegiate (17.0%), or professional (36.9%). Of the 13 studies, 4 demonstrated an increased risk of LE injury within 90 days of a diagnosed concussion (odds ratio [OR], 3.44; 95% CI, 2.99-4.42), and 6 revealed an elevated risk of injury within 1 year of concussion (OR, 1.85; 95% CI, 1.73-2.84). Increased risk was seen in professional (OR, 2.49; 95% CI, 2.40-2.72) and collegiate (OR, 2.00; 95% CI, 1.96-2.16) athletes compared with high school athletes (OR, 0.97; 95% CI, 0.89-1.05). A stepwise increase in risk of sustaining an LE injury was observed with multiple concussions, with increasing risk observed from ≥2 (OR, 2.29; 95% CI, 1.85-2.83) to ≥3 (OR, 2.86; 95% CI, 2.36-3.48) career concussions. Conclusion: An increased incidence of LE injuries was observed at 90 days and 1 year after the diagnosis of a concussion. Higher levels of competition, such as at the collegiate and professional levels, resulted in an increased risk of sustaining a subsequent LE injury after a diagnosed concussion. These results suggest an at-risk population who may benefit from injury prevention methods after a concussion. Future studies should focus on identifying which injuries are most common, during what time period athletes are most vulnerable, and methods to prevent injury after return to sports.
Neurostructural Differences in Adolescents With Treatment-Resistant Depression and Treatment Effects of Transcranial Magnetic Stimulation
Seewoo, Bhedita J. , Rodger, Jennifer , Demitrack, Mark A. , Heart, Karen, Strawn, Jeffrey R. , Croarkin, Paul E. , Croarkin, Paul E , Strawn, Jeffrey R , Port, John D.

Mayo Clinic

International Journal of Neuropsychopharmacology | January 27, 2022 | Volume: 25 | Issue: 8 | Pages: 619-630

10.1093/ijnp/pyac007 | PMID 35089358 Get It

Abstract Background Despite its morbidity and mortality, the neurobiology of treatment-resistant depression (TRD) in adolescents and the impact of treatment on this neurobiology is poorly understood. Methods Using automatic segmentation in FreeSurfer, we examined brain magnetic resonance imaging baseline volumetric differences among healthy adolescents (n = 30), adolescents with major depressive disorder (MDD) (n = 19), and adolescents with TRD (n = 34) based on objective antidepressant treatment rating criteria. A pooled subsample of adolescents with TRD were treated with 6 weeks of active (n = 18) or sham (n = 7) 10-Hz transcranial magnetic stimulation (TMS) applied to the left dorsolateral prefrontal cortex. Ten of the adolescents treated with active TMS were part of an open-label trial. The other adolescents treated with active (n = 8) or sham (n = 7) were participants from a randomized controlled trial. Results Adolescents with TRD and adolescents with MDD had decreased total amygdala (TRD and MDD: −5%, P = .032) and caudal anterior cingulate cortex volumes (TRD: −3%, P = .030; MDD: −.03%, P = .041) compared with healthy adolescents. Six weeks of active TMS increased total amygdala volumes (+4%, P < .001) and the volume of the stimulated left dorsolateral prefrontal cortex (+.4%, P = .026) in adolescents with TRD. Conclusions Amygdala volumes were reduced in this sample of adolescents with MDD and TRD. TMS may normalize this volumetric finding, raising the possibility that TMS has neurostructural frontolimbic effects in adolescents with TRD. TMS also appears to have positive effects proximal to the site of stimulation.